It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Certain immune cells and inflammatory cytokines are essential components in the tumor microenvironment to promote breast cancer progression. To identify key immune players in the tumor microenvironment, we applied highly invasive MDA-MB-231 breast cancer cell lines to co-culture with human monocyte THP-1 cells and identified CXCL7 by cytokine array as one of the increasingly secreted cytokines by THP-1 cells. Further investigations indicated that upon co-culturing, breast cancer cells secreted CSF1 to induce expression and release of CXCL7 from monocytes, which in turn acted on cancer cells to promote FAK activation, MMP13 expression, migration, and invasion. In a xenograft mouse model, administration of CXCL7 antibodies significantly reduced abundance of M2 macrophages in tumor microenvironment, as well as decreased tumor growth and distant metastasis. Clinical investigation further suggested that high CXCL7 expression is correlated with breast cancer progression and poor overall survival of patients. Overall, our study unveils an important immune cytokine, CXCL7, which is secreted by tumor infiltrating monocytes, to stimulate cancer cell migration, invasion, and metastasis, contributing to the promotion of breast cancer progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Lu-Hai, Wang 7
1 National Tsing Hua University, Institute of Molecular Medicine, Hsinchu, Taiwan (GRID:grid.38348.34) (ISNI:0000 0004 0532 0580); National Health Research Institutes, Institute of Molecular and Genomic Medicine, Miaoli, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172)
2 National Tsing Hua University, Institute of Biotechnology, Hsinchu, Taiwan (GRID:grid.38348.34) (ISNI:0000 0004 0532 0580)
3 China Medical University, Graduate Institute of Integrated Medicine and Chinese Medicine Research Center, Taichung City, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092)
4 National Taiwan University Hospital, Department of Surgery, Taipei, Taiwan (GRID:grid.412094.a) (ISNI:0000 0004 0572 7815)
5 National Tsing Hua University, Institute of Molecular and Cellular Biology, Hsinchu, Taiwan (GRID:grid.38348.34) (ISNI:0000 0004 0532 0580); National Tsing Hua University, Department of Life Sciences, Hsinchu, Taiwan (GRID:grid.38348.34) (ISNI:0000 0004 0532 0580)
6 National Tsing Hua University, Institute of Biotechnology, Hsinchu, Taiwan (GRID:grid.38348.34) (ISNI:0000 0004 0532 0580); National Tsing Hua University, Department of Medical Sciences, Hsinchu, Taiwan (GRID:grid.38348.34) (ISNI:0000 0004 0532 0580)
7 National Health Research Institutes, Institute of Molecular and Genomic Medicine, Miaoli, Taiwan (GRID:grid.59784.37) (ISNI:0000000406229172); China Medical University, Graduate Institute of Integrated Medicine and Chinese Medicine Research Center, Taichung City, Taiwan (GRID:grid.254145.3) (ISNI:0000 0001 0083 6092)




